The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

Pfizer64 enrolled

Overview

PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Allergic Rhinitis

Interventions

PF-03654764DRUG

PF-03654764 single dose 5 mg

AllegraDRUG

Fexofenadine single dose 60 mg

PF-03654764DRUG

PF-03654764 single dose 5 mg

Allegra-D

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female subjects 18-60 years allergic to ragweed pollen. * Subjects with appropriate symptom scores following exposure to ragweed in the environmental exposure unit. Exclusion Criteria: * Subjects with significant diseases other than allergic rhinitis that may interfere with the safety or efficacy of PF-03654764. * Subjects with significant symptoms of allergic rhinitis within the 2 weeks prior to screening.

Locations (1)

Pfizer Investigational Site

Kingston, Ontario, Canada

Outcomes

Primary Outcomes

Congestion scores

Time frame: 6 hours

Other allergic rhinitis symptoms

Time frame: 6 hours

Secondary Outcomes

Pharmacokinetics

Time frame: 6 hours

Blood pressure/pulse rate

Time frame: 6 hours

Adverse event reporting

Time frame: 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.